Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma

Ulrich G. Steidl, R. Fenk, I. Bruns, F. Neumann, M. Kondakci, B. Hoyer, T. Gräf, U. P. Rohr, S. Bork, R. Kronenwett, R. Haas, G. Kobbe

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Following induction therapy and 4g/m2 cyclophosphamide, a single dose of 12mg polyethyleneglycol-conjugated G-CSF (pegfilgrastim; n = 12) or daily doses of unconjugated G-CSF (8.5 μg/kg/day) (n = 12) were administered to myeloma patients. Pegfilgrastim was associated with an earlier leukocyte recovery (12 vs 14 days) and peripheral blood CD34 + cell peak (12 vs 15 days). The peripheral blood CD34 + cell peak was lower in the pegfilgrastim group (78 vs 111/μl). Following high-dose melphalan (200mg/m2) and autografting, leukocyte and platelet reconstitution was similar in both groups and stable blood counts were observed 100 days post transplant. In summary, a single dose of pegfilgrastim after chemotherapy is capable of mobilizing a sufficient number of CD34 + cells for successful autografting with early engraftment and sustained hematological reconstitution in patients with myeloma. These data provide the basis for randomized studies evaluating the optimal dose and time of pegfilgrastim as well as long-term outcome in larger cohorts of patients.

Original languageEnglish (US)
Pages (from-to)33-36
Number of pages4
JournalBone Marrow Transplantation
Volume35
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Peripheral Blood Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
Multiple Myeloma
Drug Therapy
Autologous Transplantation
Blood Cells
Leukocytes
Melphalan
Blood Group Antigens
Cyclophosphamide
Blood Platelets
Cell Count
pegfilgrastim
Transplants

Keywords

  • G-CSF
  • Multiple myeloma
  • Polyethylenglycole
  • Stem cell mobilization
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. / Steidl, Ulrich G.; Fenk, R.; Bruns, I.; Neumann, F.; Kondakci, M.; Hoyer, B.; Gräf, T.; Rohr, U. P.; Bork, S.; Kronenwett, R.; Haas, R.; Kobbe, G.

In: Bone Marrow Transplantation, Vol. 35, No. 1, 01.2005, p. 33-36.

Research output: Contribution to journalArticle

Steidl, UG, Fenk, R, Bruns, I, Neumann, F, Kondakci, M, Hoyer, B, Gräf, T, Rohr, UP, Bork, S, Kronenwett, R, Haas, R & Kobbe, G 2005, 'Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma', Bone Marrow Transplantation, vol. 35, no. 1, pp. 33-36. https://doi.org/10.1038/sj.bmt.1704702
Steidl, Ulrich G. ; Fenk, R. ; Bruns, I. ; Neumann, F. ; Kondakci, M. ; Hoyer, B. ; Gräf, T. ; Rohr, U. P. ; Bork, S. ; Kronenwett, R. ; Haas, R. ; Kobbe, G. / Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. In: Bone Marrow Transplantation. 2005 ; Vol. 35, No. 1. pp. 33-36.
@article{920795c66ad547ddbbb899b2275bcd86,
title = "Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma",
abstract = "Following induction therapy and 4g/m2 cyclophosphamide, a single dose of 12mg polyethyleneglycol-conjugated G-CSF (pegfilgrastim; n = 12) or daily doses of unconjugated G-CSF (8.5 μg/kg/day) (n = 12) were administered to myeloma patients. Pegfilgrastim was associated with an earlier leukocyte recovery (12 vs 14 days) and peripheral blood CD34 + cell peak (12 vs 15 days). The peripheral blood CD34 + cell peak was lower in the pegfilgrastim group (78 vs 111/μl). Following high-dose melphalan (200mg/m2) and autografting, leukocyte and platelet reconstitution was similar in both groups and stable blood counts were observed 100 days post transplant. In summary, a single dose of pegfilgrastim after chemotherapy is capable of mobilizing a sufficient number of CD34 + cells for successful autografting with early engraftment and sustained hematological reconstitution in patients with myeloma. These data provide the basis for randomized studies evaluating the optimal dose and time of pegfilgrastim as well as long-term outcome in larger cohorts of patients.",
keywords = "G-CSF, Multiple myeloma, Polyethylenglycole, Stem cell mobilization, Stem cell transplantation",
author = "Steidl, {Ulrich G.} and R. Fenk and I. Bruns and F. Neumann and M. Kondakci and B. Hoyer and T. Gr{\"a}f and Rohr, {U. P.} and S. Bork and R. Kronenwett and R. Haas and G. Kobbe",
year = "2005",
month = "1",
doi = "10.1038/sj.bmt.1704702",
language = "English (US)",
volume = "35",
pages = "33--36",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma

AU - Steidl, Ulrich G.

AU - Fenk, R.

AU - Bruns, I.

AU - Neumann, F.

AU - Kondakci, M.

AU - Hoyer, B.

AU - Gräf, T.

AU - Rohr, U. P.

AU - Bork, S.

AU - Kronenwett, R.

AU - Haas, R.

AU - Kobbe, G.

PY - 2005/1

Y1 - 2005/1

N2 - Following induction therapy and 4g/m2 cyclophosphamide, a single dose of 12mg polyethyleneglycol-conjugated G-CSF (pegfilgrastim; n = 12) or daily doses of unconjugated G-CSF (8.5 μg/kg/day) (n = 12) were administered to myeloma patients. Pegfilgrastim was associated with an earlier leukocyte recovery (12 vs 14 days) and peripheral blood CD34 + cell peak (12 vs 15 days). The peripheral blood CD34 + cell peak was lower in the pegfilgrastim group (78 vs 111/μl). Following high-dose melphalan (200mg/m2) and autografting, leukocyte and platelet reconstitution was similar in both groups and stable blood counts were observed 100 days post transplant. In summary, a single dose of pegfilgrastim after chemotherapy is capable of mobilizing a sufficient number of CD34 + cells for successful autografting with early engraftment and sustained hematological reconstitution in patients with myeloma. These data provide the basis for randomized studies evaluating the optimal dose and time of pegfilgrastim as well as long-term outcome in larger cohorts of patients.

AB - Following induction therapy and 4g/m2 cyclophosphamide, a single dose of 12mg polyethyleneglycol-conjugated G-CSF (pegfilgrastim; n = 12) or daily doses of unconjugated G-CSF (8.5 μg/kg/day) (n = 12) were administered to myeloma patients. Pegfilgrastim was associated with an earlier leukocyte recovery (12 vs 14 days) and peripheral blood CD34 + cell peak (12 vs 15 days). The peripheral blood CD34 + cell peak was lower in the pegfilgrastim group (78 vs 111/μl). Following high-dose melphalan (200mg/m2) and autografting, leukocyte and platelet reconstitution was similar in both groups and stable blood counts were observed 100 days post transplant. In summary, a single dose of pegfilgrastim after chemotherapy is capable of mobilizing a sufficient number of CD34 + cells for successful autografting with early engraftment and sustained hematological reconstitution in patients with myeloma. These data provide the basis for randomized studies evaluating the optimal dose and time of pegfilgrastim as well as long-term outcome in larger cohorts of patients.

KW - G-CSF

KW - Multiple myeloma

KW - Polyethylenglycole

KW - Stem cell mobilization

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=19944429579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944429579&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704702

DO - 10.1038/sj.bmt.1704702

M3 - Article

VL - 35

SP - 33

EP - 36

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -